UniQure's Huntington's gene therapy shows sustained but narrowing benefit at four years
Long-term follow-up data for UniQure's AMT-130 gene therapy indicate continued benefit in Huntington's disease, though the magnitude of effect has diminished over time — raising durability questions for patients and the field.
New data from UniQure's ongoing study of AMT-130, an AAV5-delivered gene therapy targeting huntingtin (HTT) mRNA in Huntington's disease, show that treated participants continue to demonstrate measurable benefit compared with historical controls four years after dosing. However, the effect size has narrowed compared with earlier time points, prompting questions about whether the therapy's benefit is durable at clinically meaningful levels over the longer term.
A *Stat News* report draws on patient perspectives to highlight the gap between the concerns driving Wall Street scrutiny — centred on whether narrowing efficacy signals undermine the therapy's commercial case — and those of people living with Huntington's disease, for whom any sustained slowing of a uniformly fatal condition carries significant personal weight. The piece quotes a patient participant who describes remaining unfazed by the waning signal, a framing that underscores the complexity of interpreting surrogate endpoints from the perspective of those most affected.
AMT-130 uses a microRNA-based approach delivered directly to the striatum via stereotactic neurosurgical infusion. The four-year data have not yet been published in a peer-reviewed journal; the figures described derive from conference and investor presentations. Genetic counsellors and clinicians working with Huntington's families will note that the therapy remains investigational. Researchers tracking the gene therapy field will be watching how UniQure interprets these durability findings as it navigates potential regulatory discussions.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
A gene therapy called AMT-130, developed by a company called UniQure, is being studied as a potential treatment for Huntington's disease — an inherited condition that progressively damages the nervous system. Data collected four years after treatment in a small number of participants suggest the therapy may still be providing some benefit, but the level of benefit appears to have reduced compared with what was seen earlier. The company's scientists are still studying why this might be and what it means for people in the longer term. This therapy is still being researched and is not yet an approved treatment. A news article also highlighted that patients themselves — unlike financial analysts — often find even a modest slowing of the disease meaningful. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-10-01STAT+: Why a Huntington's patient isn't fazed by the waning effect of UniQure's gene therapy